BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
|
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [21] CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
    Pegoraro, V
    Heiman, F.
    di Nola, L.
    Pulimeno, S.
    Burgio, L.
    VALUE IN HEALTH, 2018, 21 : S329 - S330
  • [22] Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
    Martinez, James M.
    Garce, Sandra
    Anglin, Greg
    Hodsdon, Michael
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [23] Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    Garces, Sandra
    NEUROLOGY, 2019, 92 (15)
  • [24] Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric M.
    Garces, Sandra
    CEPHALALGIA, 2020, 40 (09) : 978 - 989
  • [25] Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
    Ruff, D. D.
    Ford, J. H.
    Tockhorn-Heidenreich, A.
    Stauffer, V. L.
    Govindan, S.
    Aurora, S. K.
    Terwindt, G. M.
    Goadsby, P. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 609 - 618
  • [26] A Real-World Perspective of Patients With Episodic Migraine or Chronic Migraine Prescribed AJOVY in the United States
    Cohen, J. M.
    Pandya, S.
    Krasenbaum, L. J.
    Thompson, S. F.
    Chen, C.
    Tangirala, K.
    HEADACHE, 2020, 60 : 5 - 6
  • [27] Healthcare Resource Use and Costs among Patients with Chronic and Episodic Migraine in the United States
    Stokes, Michael E.
    Varon, Sepideh F.
    Sullivan, Sean D.
    Blumenfeld, Andrew M.
    Lipton, Richard B.
    Goadsby, Peter J.
    Wilcox, Teresa K.
    NEUROLOGY, 2011, 76 (09) : A468 - A468
  • [28] Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine
    Day, Kathleen A.
    Ament, Michael
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Rettiganti, Mallikarjuna
    Pearlman, Eric M.
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
  • [29] Sustained response of galcanezumab in migraine prevention: Patient--level data from a post hoc analysis in patients with episodic or chronic migraine
    Tepper, Stewart J.
    Dong, Yan
    Vincent, Maurice
    Wietecha, Linda A.
    HEADACHE, 2023, 63 (10): : 1380 - 1390
  • [30] Treatment with Galcanezumab in Patients with Episodic Migraine: Results from the OpenLabel Phase of the PERSIST Study
    Yu, Shengyuan
    Zhou, Jiying
    Zhuang, Junpeng
    Liu, Hui
    Qian, Chenxi
    NEUROLOGY, 2023, 100 (17)
12345